Posts tagged hospitalization
HCW starts Aviragen Therapeutics at buy

H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday.

Aviragen is a developing three direct-acting antiviral (DAA) compounds, each in Phase 2 development, including oral vapendavir, which targets human rhinovirus (HRV), causing the common cold; oral BTA585, which targets respiratory syncytial virus; and BTA074, which is a topical targeting human papillomavirus for condyloma.

Read More
BTIG starts Entellus Medical at buy

BTIG Research has initiated coverage of Entellus Medical (NASDAQ:ENTL) with a ‘buy” rating and $22 price target. The stock closed at $18.58 on Monday.

“Entellus Medical benefits patients, physicians, and payers by moving balloon sinus dilation (BSD) out of the hospital and into physician offices,” writes analyst Dr. Sean Lavin.

Read More